

WD

#13
12/15/99
J. Melun


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Coleman et al.

Application Number: 08/972,301

Filed: November 18, 1997

Title: Endothelial-Monocyte
Activating Polypeptide III



Group Art Unit: 1646

Examiner: E. Kemmerer

Attny. Docket No.: PF206D1

STATEMENT UNDER 37 C.F.R. 1.821 and 1.825

Assistant Commissioner For Patents
Washington, D.C. 20231

Sir:

Applicants hereby certify under 37 C.F.R. §§1.821(f) and 1.825(a) and (b) that the substitute sequence listing pages filed herein are identical to the computer readable form submitted herewith. Support for the amendment to SEQ ID NO:6 is found in the sequence described at page 29, lines 17-18 in the parent application, U.S. Serial No: 08/483,534.

Moreover, applicants hereby certify under 37 C.F.R. §§1.821(g) and 1.825(a) that the substitute sequence listing contains no new matter.

No fee is believed due in connection with this submission. However, should a fee be required, the Assistant Commissioner is hereby authorized to charge such fee to Deposit Account No. 08-3425. A duplicate of this sheet is enclosed.

Respectfully submitted

Michelle S. Marks (Reg. No. 41,971)
Attorney for Applicants

Date: 12/3/99

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 610-5761 (telephone)

MSM/mbp